ALFA Finder| Revenue guidance | 17.5% → 25.0% Raised by 7.5 percentage points |
|---|---|
| Management target | Revenue 25.0% FY27 |
| Revenue growth | Q2 +40% YoY; H1 +39% YoY |
|---|---|
| Margins | EBITDA margin 14.4% Q2 vs 11.2% LY |
| Order book | API order book 4-6 months; cost pass-through clauses |
| Demand visibility | Pharma demand encouraging; utilization 90-95% |
| Management confidence | High; reiterated 25%+ growth and 15-17% EBITDA |
Growth
H1 FY27 revenue INR1,551 cr (+39% YoY), EBITDA INR227 cr (14.5%), PAT INR130 cr vs INR64 cr. Exports ~28% of H1 revenue.
Outlook
FY27 revenue growth 25%+ with 14-15% EBITDA margin. Ibuprofen capacity 12,000 to 18,000 MTPA targeted FY28; INR500 cr projects via internal accruals.
Risks
Ibuprofen prices flat for 2-3 quarters; other expenses 14.5% of sales; higher finance cost; freight and power cost pressure.
Investor Presentation filed with BSE, NSE: IOLCP. Summary written with AI assistance from the document.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹183.29
- Market cap
- ₹5,380 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 26.5×Sector 43.0×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals delivered strong Q2 results with significant profitability improvements, driven by non-Ibuprofen API growth and cost efficiencies, despite rising raw material prices.
- Call
- Guides 25% growth
IOL Chemicals and Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue ₹795 Cr (+40.1% YoY), EBITDA ₹114.9 Cr (14.4% margin), PAT ₹65 Cr (+116.8%). H1 revenue ₹1,551 Cr (+38.6%). Pivoting to high-value APIs with ₹495 Cr capex plan.
IOL Chemicals and Pharmaceuticals Results Update
IOL Chemicals reported record quarterly revenue, EBITDA and profit for Q2 FY27 and half-year results. Standalone growth was strong, with margins expanding year-on-year.
IOL Chemicals and Pharmaceuticals Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 117.0% YoY
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹795 Cr (+40.1% YoY) and net profit of ₹65.1 Cr (+117.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +117.0% YoY
IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
IOL Chemicals and Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.